NRx Pharmaceuticals, Inc. (NRXP) 10-Year Financial Performance & Capital Metrics

NRXP • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutNRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.Show more

Revenue $0
EBITDA -$20M +28.6%
Net Income -$25M +16.7%
EPS (Diluted) -2.39 +39.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -18.26 +92.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 20 (bottom 20%)
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 38.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-86.76%

EPS CAGR

10Y-

5Y-

3Y-

TTM-44.83%

ROCE

10Y Avg-186.53%

5Y Avg-371.63%

3Y Avg-285.69%

Latest-

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	1.01M	0	2K	2K	4K	5K	5K
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	-1.01M	0	-2K	-2K	-4K	-5K	-5K
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	1%	-	0%	-1%	-0.25%	0%
Operating Expenses+	0	0	713.19K	22.06M	95.2M	44.33M	27.58M	19.7M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	0	1.01M	713.19K	11.43M	74.94M	27.3M	14.21M	13.5M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	0	0	0	10.63M	20.26M	17.03M	13.37M	6.2M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	0	-1.01M	-713.19K	-22.06M	-95.2M	-44.34M	-27.59M	-19.7M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-	0.29%	-29.93%	-3.32%	0.53%	0.38%	0.29%
EBITDA+	-105K	82.41K	492.63K	-22.06M	-95.2M	-44.33M	-27.58M	-19.7M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	1.78%	4.98%	-45.78%	-3.32%	0.53%	0.38%	0.29%
D&A (Non-Cash Add-back)	52.52K	0	0	2K	2K	4K	5K	5K
EBIT	-105K	82.41K	492.63K	-51.72M	-93.05M	-39.75M	-30.03M	-24.05M
Net Interest Income+	0	0	1.21M	-55.94K	-17.98K	249K	374K	-1.03M
Interest Income	0	1.09M	1.21M	56	18	249K	494K	44K
Interest Expense	0	0	0	56K	18K	0	120K	1.08M
Other Income/Expense	-105K	1.09M	1.21M	-29.72M	2.14M	4.58M	-2.56M	-5.42M
Pretax Income+	-105K	82.41K	492.63K	-51.78M	-93.06M	-39.75M	-30.15M	-25.13M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	16.31K	84.21K	0	0	0	0	0
Effective Tax Rate %	1%	0.8%	0.83%	1%	1%	1%	1%	1%
Net Income+	-105K	66.1K	408.43K	-51.78M	-93.06M	-39.75M	-30.15M	-25.13M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	1.63%	5.18%	-127.77%	-0.8%	0.57%	0.24%	0.17%
Net Income (Continuing)	-105K	66.1K	408.43K	-51.78M	-93.06M	-39.75M	-30.15M	-25.13M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.12	0.07	0.80	-1.51	-7.44	-0.60	-3.98	-2.39
EPS Growth %	-	1.62%	9.8%	-2.89%	-3.93%	0.92%	-5.63%	0.4%
EPS (Basic)	-0.12	0.07	0.80	-1.51	-7.44	-0.60	-3.98	-2.39
Diluted Shares Outstanding	903.55K	892.5K	508.83K	546.59K	46.92M	65.77M	7.58M	10.52M
Basic Shares Outstanding	903.55K	892.5K	508.83K	546.59K	46.92M	65.77M	7.58M	10.52M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	536.38K	30.19K	69.49K	2.93M	32.71M	25.8M	6.88M	3.3M
Cash & Short-Term Investments	449.37K	11.08K	6	1.86M	27.61M	20.05M	4.59M	1.44M
Cash Only	449.37K	11.08K	6	1.86M	27.61M	20.05M	4.59M	1.44M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	831K	0	7K	6K	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	214K	0	0	0	0
Days Inventory Outstanding	-	-	-	39.05K	-	-	-	-
Other Current Assets	87K	19.11K	0	26K	0	0	0	0
Total Non-Current Assets+	69.03M	70.77M	32.01M	11K	15K	21K	431K	349K
Property, Plant & Equipment	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	69.03M	70.77M	32.01M	0	0	0	0	0
Other Non-Current Assets	0	0	0	11K	15K	21K	431K	349K
Total Assets+	69.57M	70.8M	32.07M	2.94M	32.73M	25.82M	7.32M	3.65M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	0.02%	-0.55%	-0.91%	10.13%	-0.21%	-0.72%	-0.5%
Total Current Liabilities+	93.17K	567.41K	622.44K	46.16M	11.92M	15.59M	19.05M	21.86M
Accounts Payable	85.67K	551.1K	0	3.15M	3.69M	2.08M	4.63M	4.13M
Days Payables Outstanding	-	199.85	-	575.42K	672.88K	189.44K	338.14K	301.49K
Short-Term Debt	0	0	0	249K	518K	7.7M	9.16M	1.57M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	7.5K	0	622.44K	0	4.87M	37K	4.42M	10.93M
Current Ratio	5.76x	0.05x	0.11x	0.06x	2.74x	1.66x	0.36x	0.15x
Quick Ratio	5.76x	0.05x	0.11x	0.06x	2.74x	1.66x	0.36x	0.15x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	690K	1.95M	548K	0	2.82M	0	5.01M
Long-Term Debt	0	690K	1.95M	548K	0	2.82M	0	5.01M
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	93.17K	1.26M	2.57M	46.71M	11.92M	18.41M	19.05M	26.87M
Total Debt+	0	690K	1.95M	797K	518K	10.53M	9.16M	6.58M
Net Debt	-449.37K	678.92K	1.95M	-1.06M	-27.09M	-9.53M	4.57M	5.13M
Debt / Equity	-	0.01x	0.07x	-	0.02x	1.42x	-	-
Debt / EBITDA	-	8.37x	3.96x	-	-	-	-	-
Net Debt / EBITDA	-	8.24x	3.96x	-	-	-	-	-
Interest Coverage	-	-	-	-393.95x	-5288.94x	-	-229.89x	-18.26x
Total Equity+	69.47M	69.54M	29.5M	-43.77M	20.81M	7.41M	-11.73M	-23.22M
Equity Growth %	-	0%	-0.58%	-2.48%	1.48%	-0.64%	-2.58%	-0.98%
Book Value per Share	76.89	77.91	57.98	-80.08	0.44	0.11	-1.55	-2.21
Total Shareholders' Equity	69.47M	69.54M	29.5M	-43.77M	20.81M	7.41M	-11.73M	-23.22M
Common Stock	64.48M	64.54M	24.5M	43K	59K	67K	84K	15K
Retained Earnings	-105.03K	-38.93K	369.5K	-90.18M	-183.24M	-223M	-253.15M	-278.27M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	-3K	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-135.81K	-473.19K	-792.73K	-2.27M	-37.7M	-39.76M	-21.66M	-10.64M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-2.48%	-0.68%	-1.86%	-15.65%	-0.05%	0.46%	0.51%
Net Income	-105.03K	66.1K	408.43K	-51.78M	-93.06M	-39.75M	-30.15M	-25.13M
Depreciation & Amortization	0	0	0	2K	2K	4K	5K	5K
Stock-Based Compensation	0	0	0	730K	7.79M	3.63M	387K	486K
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	-115.11K	-1.55M	-1.21M	45.33M	52.47M	-4.33M	2.94M	8.71M
Working Capital Changes	-1.33K	549.63K	4.66K	3.45M	-4.9M	699K	5.16M	5.29M
Change in Receivables	0	0	0	-831K	831K	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	85.67K	465.43K	0	1.18M	-19K	-1.61M	2.65M	-5.22M
Cash from Investing+	-69M	-647.61K	40.25M	-2K	-7K	-10K	-3K	0
Capital Expenditures	0	0	0	-2K	-7K	-10K	-3K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	-69M	-647.61K	0	0	0	0	0	0
Cash from Financing+	69.59M	682.5K	-39.46M	3.25M	63.46M	32.21M	6.2M	7.49M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	27.75M	10K	0	3.07M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-135.81K	-473.19K	-792.73K	-2.27M	-37.71M	-39.77M	-21.66M	-10.64M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-2.48%	-0.68%	-1.86%	-15.63%	-0.05%	0.46%	0.51%
FCF per Share	-0.15	-0.53	-1.56	-4.15	-0.80	-0.60	-2.86	-1.01
FCF Conversion (FCF/Net Income)	1.29x	-7.16x	-1.94x	0.04x	0.41x	1.00x	0.72x	0.42x
Interest Paid	0	0	0	0	0	0	885K	374K
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-0.15%	0.1%	0.82%	-	-447.29%	-281.79%	-	-
Return on Invested Capital (ROIC)	-	-1.08%	-1.05%	-	-	-	-	-
Debt / Equity	-	0.01x	0.07x	-	0.02x	1.42x	-	-
Interest Coverage	-	-	-	-393.95x	-5288.94x	-	-229.89x	-18.26x
FCF Conversion	1.29x	-7.16x	-1.94x	0.04x	0.41x	1.00x	0.72x	0.42x

Frequently Asked Questions

Growth & Financials

NRx Pharmaceuticals, Inc. (NRXP) reported $0.2M in revenue for fiscal year 2024.

NRx Pharmaceuticals, Inc. (NRXP) grew revenue by 0.0% over the past year. Growth has been modest.

NRx Pharmaceuticals, Inc. (NRXP) reported a net loss of $38.1M for fiscal year 2024.

Dividend & Returns

NRx Pharmaceuticals, Inc. (NRXP) had negative free cash flow of $11.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

NRx Pharmaceuticals, Inc. (NRXP) 10-Year Financial Performance & Capital Metrics

NRXP • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $0
EBITDA -$20M +28.6%
Net Income -$25M +16.7%
EPS (Diluted) -2.39 +39.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -18.26 +92.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 20 (bottom 20%)
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 38.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-86.76%

EPS CAGR

10Y-

5Y-

3Y-

TTM-44.83%

ROCE

10Y Avg-186.53%

5Y Avg-371.63%

3Y Avg-285.69%

Latest-

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	1.01M	0	2K	2K	4K	5K	5K
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	-1.01M	0	-2K	-2K	-4K	-5K	-5K
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	1%	-	0%	-1%	-0.25%	0%
Operating Expenses+	0	0	713.19K	22.06M	95.2M	44.33M	27.58M	19.7M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	0	1.01M	713.19K	11.43M	74.94M	27.3M	14.21M	13.5M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	0	0	0	10.63M	20.26M	17.03M	13.37M	6.2M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	0	-1.01M	-713.19K	-22.06M	-95.2M	-44.34M	-27.59M	-19.7M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-	0.29%	-29.93%	-3.32%	0.53%	0.38%	0.29%
EBITDA+	-105K	82.41K	492.63K	-22.06M	-95.2M	-44.33M	-27.58M	-19.7M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	1.78%	4.98%	-45.78%	-3.32%	0.53%	0.38%	0.29%
D&A (Non-Cash Add-back)	52.52K	0	0	2K	2K	4K	5K	5K
EBIT	-105K	82.41K	492.63K	-51.72M	-93.05M	-39.75M	-30.03M	-24.05M
Net Interest Income+	0	0	1.21M	-55.94K	-17.98K	249K	374K	-1.03M
Interest Income	0	1.09M	1.21M	56	18	249K	494K	44K
Interest Expense	0	0	0	56K	18K	0	120K	1.08M
Other Income/Expense	-105K	1.09M	1.21M	-29.72M	2.14M	4.58M	-2.56M	-5.42M
Pretax Income+	-105K	82.41K	492.63K	-51.78M	-93.06M	-39.75M	-30.15M	-25.13M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	16.31K	84.21K	0	0	0	0	0
Effective Tax Rate %	1%	0.8%	0.83%	1%	1%	1%	1%	1%
Net Income+	-105K	66.1K	408.43K	-51.78M	-93.06M	-39.75M	-30.15M	-25.13M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	1.63%	5.18%	-127.77%	-0.8%	0.57%	0.24%	0.17%
Net Income (Continuing)	-105K	66.1K	408.43K	-51.78M	-93.06M	-39.75M	-30.15M	-25.13M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.12	0.07	0.80	-1.51	-7.44	-0.60	-3.98	-2.39
EPS Growth %	-	1.62%	9.8%	-2.89%	-3.93%	0.92%	-5.63%	0.4%
EPS (Basic)	-0.12	0.07	0.80	-1.51	-7.44	-0.60	-3.98	-2.39
Diluted Shares Outstanding	903.55K	892.5K	508.83K	546.59K	46.92M	65.77M	7.58M	10.52M
Basic Shares Outstanding	903.55K	892.5K	508.83K	546.59K	46.92M	65.77M	7.58M	10.52M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	536.38K	30.19K	69.49K	2.93M	32.71M	25.8M	6.88M	3.3M
Cash & Short-Term Investments	449.37K	11.08K	6	1.86M	27.61M	20.05M	4.59M	1.44M
Cash Only	449.37K	11.08K	6	1.86M	27.61M	20.05M	4.59M	1.44M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	831K	0	7K	6K	0
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	214K	0	0	0	0
Days Inventory Outstanding	-	-	-	39.05K	-	-	-	-
Other Current Assets	87K	19.11K	0	26K	0	0	0	0
Total Non-Current Assets+	69.03M	70.77M	32.01M	11K	15K	21K	431K	349K
Property, Plant & Equipment	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	69.03M	70.77M	32.01M	0	0	0	0	0
Other Non-Current Assets	0	0	0	11K	15K	21K	431K	349K
Total Assets+	69.57M	70.8M	32.07M	2.94M	32.73M	25.82M	7.32M	3.65M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	0.02%	-0.55%	-0.91%	10.13%	-0.21%	-0.72%	-0.5%
Total Current Liabilities+	93.17K	567.41K	622.44K	46.16M	11.92M	15.59M	19.05M	21.86M
Accounts Payable	85.67K	551.1K	0	3.15M	3.69M	2.08M	4.63M	4.13M
Days Payables Outstanding	-	199.85	-	575.42K	672.88K	189.44K	338.14K	301.49K
Short-Term Debt	0	0	0	249K	518K	7.7M	9.16M	1.57M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	7.5K	0	622.44K	0	4.87M	37K	4.42M	10.93M
Current Ratio	5.76x	0.05x	0.11x	0.06x	2.74x	1.66x	0.36x	0.15x
Quick Ratio	5.76x	0.05x	0.11x	0.06x	2.74x	1.66x	0.36x	0.15x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	690K	1.95M	548K	0	2.82M	0	5.01M
Long-Term Debt	0	690K	1.95M	548K	0	2.82M	0	5.01M
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	93.17K	1.26M	2.57M	46.71M	11.92M	18.41M	19.05M	26.87M
Total Debt+	0	690K	1.95M	797K	518K	10.53M	9.16M	6.58M
Net Debt	-449.37K	678.92K	1.95M	-1.06M	-27.09M	-9.53M	4.57M	5.13M
Debt / Equity	-	0.01x	0.07x	-	0.02x	1.42x	-	-
Debt / EBITDA	-	8.37x	3.96x	-	-	-	-	-
Net Debt / EBITDA	-	8.24x	3.96x	-	-	-	-	-
Interest Coverage	-	-	-	-393.95x	-5288.94x	-	-229.89x	-18.26x
Total Equity+	69.47M	69.54M	29.5M	-43.77M	20.81M	7.41M	-11.73M	-23.22M
Equity Growth %	-	0%	-0.58%	-2.48%	1.48%	-0.64%	-2.58%	-0.98%
Book Value per Share	76.89	77.91	57.98	-80.08	0.44	0.11	-1.55	-2.21
Total Shareholders' Equity	69.47M	69.54M	29.5M	-43.77M	20.81M	7.41M	-11.73M	-23.22M
Common Stock	64.48M	64.54M	24.5M	43K	59K	67K	84K	15K
Retained Earnings	-105.03K	-38.93K	369.5K	-90.18M	-183.24M	-223M	-253.15M	-278.27M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	-3K	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-135.81K	-473.19K	-792.73K	-2.27M	-37.7M	-39.76M	-21.66M	-10.64M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-2.48%	-0.68%	-1.86%	-15.65%	-0.05%	0.46%	0.51%
Net Income	-105.03K	66.1K	408.43K	-51.78M	-93.06M	-39.75M	-30.15M	-25.13M
Depreciation & Amortization	0	0	0	2K	2K	4K	5K	5K
Stock-Based Compensation	0	0	0	730K	7.79M	3.63M	387K	486K
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	-115.11K	-1.55M	-1.21M	45.33M	52.47M	-4.33M	2.94M	8.71M
Working Capital Changes	-1.33K	549.63K	4.66K	3.45M	-4.9M	699K	5.16M	5.29M
Change in Receivables	0	0	0	-831K	831K	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	85.67K	465.43K	0	1.18M	-19K	-1.61M	2.65M	-5.22M
Cash from Investing+	-69M	-647.61K	40.25M	-2K	-7K	-10K	-3K	0
Capital Expenditures	0	0	0	-2K	-7K	-10K	-3K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	-69M	-647.61K	0	0	0	0	0	0
Cash from Financing+	69.59M	682.5K	-39.46M	3.25M	63.46M	32.21M	6.2M	7.49M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	27.75M	10K	0	3.07M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-135.81K	-473.19K	-792.73K	-2.27M	-37.71M	-39.77M	-21.66M	-10.64M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-2.48%	-0.68%	-1.86%	-15.63%	-0.05%	0.46%	0.51%
FCF per Share	-0.15	-0.53	-1.56	-4.15	-0.80	-0.60	-2.86	-1.01
FCF Conversion (FCF/Net Income)	1.29x	-7.16x	-1.94x	0.04x	0.41x	1.00x	0.72x	0.42x
Interest Paid	0	0	0	0	0	0	885K	374K
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-0.15%	0.1%	0.82%	-	-447.29%	-281.79%	-	-
Return on Invested Capital (ROIC)	-	-1.08%	-1.05%	-	-	-	-	-
Debt / Equity	-	0.01x	0.07x	-	0.02x	1.42x	-	-
Interest Coverage	-	-	-	-393.95x	-5288.94x	-	-229.89x	-18.26x
FCF Conversion	1.29x	-7.16x	-1.94x	0.04x	0.41x	1.00x	0.72x	0.42x

Frequently Asked Questions

Growth & Financials

NRx Pharmaceuticals, Inc. (NRXP) reported $0.2M in revenue for fiscal year 2024.

NRx Pharmaceuticals, Inc. (NRXP) grew revenue by 0.0% over the past year. Growth has been modest.

NRx Pharmaceuticals, Inc. (NRXP) reported a net loss of $38.1M for fiscal year 2024.

Dividend & Returns

NRx Pharmaceuticals, Inc. (NRXP) had negative free cash flow of $11.9M in fiscal year 2024, likely due to heavy capital investments.